Challenges have emerged following the revival of nitric oxide (NO) from "something old", a simple gas derived from nitrogen and oxygen with a role in the early stages of evolution, into "something new", an endogenously formed biological mediator regulating a wide variety of physiological functions. Although pain is a common sensation, it encompasses multiple neurobiologic components of which NO is only one. In pain research, the study of NO is complicated by convoluted problems related mostly to the effects of NO, which are pro-or antinociceptive depending on the circumstances. This dual function reflects the two faces of the NO molecule described in physiology. This review covers current information about NO and its implications in pain mechanisms. In addition, it follows the pain pathways, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 4
Introduction
The revival of nitric oxide (NO) indicates that "something simple and something old" may now be "new" again. It should be remembered that NO is a simple gas (1) derived from nitrogen and oxygen, and it played a crucial role in the early stages of evolution (2). NO may have constituted a critical defence mechanism for primitive microorganisms by counteracting oxidative destruction and giving them an evolutionary advantage (2). Not only is NO an ancient and widely used regulator of the life history of different species of eukaryotes and solitary ascidians (3), but the presence of NO was observed in plants much earlier than in animals (4). Discovered in the 17 th century by Jan B. Helmont (5) and studied under the name "phlogisticated nitrous air" by Joseph Priestley (6), NO was regarded for many years as an environmental pollutant (7). It became "something new" in 1992 when it received intense media coverage due to its stature as a biological messenger (8) and became the molecule of the year (9) . The 1998 Nobel Prize in Physiology or Medicine was awarded for "the first discovery that a gas can act as a signal molecule", emphasising that NO is a biological mediator produced by mammalian cells (10) . The fascinating history of NO thereafter continued, with extensive research showing that NO plays an important role in most human organ systems, and in neurotransmission, immune defence, regulation of death cells and cell motility (10) .
It was reported that NO modulates spinal and sensory neuron excitability that contributes to different pain states. However, investigating the implications of this molecule in nociception remains a challenging task. The aim of the present review is to summarise the contributions of NO to pain mechanisms, both in peripheral and central nociceptive transmission, and to elucidate therapeutic implications of its action.
2. Nitric oxide biosynthesis and pain 2.1. Basic physiology In biological systems, NO is a molecular gas generated from L-arginine (11) and molecular oxygen by the activity of nitric oxide synthase (NOS). L-citrulline results from this reaction and is shunted into a metabolic pathway that regenerates free L-arginine ( Fig.1 ). Furchgott first identified NO synthases implicated in NO generation in experiments on the aortas of rabbits (12) . The different forms of NO synthase have been identified and named based upon the cells from which they were first isolated: neuronal NOS (nNOS, type 1 NOS) (13);
inducible NOS, induced in macrophages upon stimulation with bacterial endotoxines and cytokines (iNOS, type 2 NOS) (14) ; endothelial NOS (eNOS, type 3 NOS) (15) ; and in some tissues they may exist in mitochondria (mNOS) (16) . The NOS enzymes differ not only in their localization, but also in their function. The two calcium dependent constitutive NOSseNOS and nNOS, generate small amounts of NO, while iNOS production that is independent of intracellular calcium concentrations generates NO levels able to damage cells and microorganisms (17) . These enzymes are distinct proteins encoded by genes on disparate chromosomes, but all of them have the same genomic structure and all of them facilitate the addition of the guanidino nitrogen of the amino acid arginine to molecular oxygen, producing NO and water ( Fig.1 ) (15) . The enzyme consists of an oxygenase domain and a reductase domain, each with its own catalytic activity (15) (Fig.2 
Nitric oxide synthases (NOSs) in relation to pain
Knowledge about the role of NO in different types of pain has been derived primarily from animal experiments examining the expression of the NOS isoforms in relation to a nociceptive stimulus. The idea that nNOS contributes to the role of NO in nociception is supported by the observation that its expression is rapidly upregulated in the dorsal horn neurons of the spinal cord after a peripheral noxious stimulation (18, 19). Genetic knockout and pharmacologic inhibition of neuronal nNOS attenuate nerve injury-induced mechanical hypersensitivity in mice, suggesting that nNOS may participate in the development and maintenance of mechanical hypersensitivity after nerve injury (20).
In mice lacking iNOS, there were fewer and smaller regenerating myelinated fibres and slowed reinnervation of muscle endplates distal to the injury zone, demonstrating that iNOS is a critical factor in the repair of injured tissue (21). Inducible NOS is upregulated in the inflamed tissue (22) and is involved in the development of hypersensitivity to pain in inflammatory and neuropathic pain models (23). These findings lead to the conclusion that 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   8 The presence of BH 4 is important in dopamine formation, and in several neurotransmitters and NO formation, and any deficiency leads to the formation of other reactive oxygen species (ROS) (15) . The role of BH4 as an intrinsic regulator in neuropathic and inflammatory pain was confirmed by increasing BH4 synthesis in the rat sensory neurons in response to both axonal injury and peripheral inflammation, and also by the observation that blocking the BH4 synthesis reduced neuropathic and inflammatory pain (31). The enzyme implicated in BH4 synthesis, GTP cyclohydrolase (GCH1), is a key modulator of peripheral neuropathic and inflammatory pain (32) (Fig.3) . In animal models of both neuropathic pain and inflammatory pain, injecting GTP cyclohydrolase inhibitor, called 2, 4-diamino-6-hydroxypyrimidine (DAHP), alleviated hypersensitivity to pain and reduced the levels of NO (31, 32).
Furthermore, the animal models were correlated to clinical pain when a "pain-protective"
haplotype of the GCH1 gene was identified (31). This haplotype that reduces BH4 upregulation was protective against persistent neuropathic pain, and it decreased pain sensitivity in low back pain patients following herniated disc surgery and also in normal volunteers in an experimental pain model (31). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In the absence of substrate and cofactors, NOS no longer produces NO, but transfers the free electrons and produces free oxygen radicals (34).
(33). Noxious stimuli induce the upregulation of GTP cyclohydrolase (GCH1). BH4 modulates several

Page 8 of 38 Acta Anaesthesiologica Scandinavica
Reactive oxidative species (oxygen/nitrogen) and pain
Reactive oxidative species are highly reactive chemicals that contain only oxygen atoms (reactive oxygen species-ROS) or both nitrogen and oxygen (reactive nitrogen species-RNS).
ROS react easily with other molecules, resulting in potentially damaging modifications (35). The stimulation of cyclic guanosine monophosphate cGMP-dependent kinases is one of the numerous direct biological actions of NO (57). NO activates the guanylyl cyclase and increases the synthesis of cyclic guanosine monophosphate (58) . The major target of NO is NO-sensitive guanylyl cyclase (GC) or soluble guanylyl cyclase (sGC). Activation of guanylyl cyclase results in conversion of guanosine triphosphate to the second messenger cGMP (59) . The NO/cGMP signalling cascade (Fig.4) is important in the cardiovascular and nervous systems, where it controls smooth muscle relaxation and modulation of synaptic transmission (60) . The second messenger cGMP has several targets, including cGMP-dependent protein kinase I (PKG-I) and PKG-II, activation of cGMP-regulated phosphodiesterase and cGMP-regulated ion channels (60) . PKG-I is expressed in the spinal cord and is involved in the facilitation of synaptic transmission of nociceptive stimuli in the spinal cord (61, 62) and also in substance P synthesis (32).
The NO-cGMP pathway in pain
The NO-cGMP signalling pathway is present in neurons of the spinal cord and contributes to the development of hyperalgesia in animal models of pain (63, 64, 65) through PKG-I activation (66) . It was recently demonstrated that during spinal nociceptive processing, cGMP produced by NO-GC may activate signalling pathways different from those activated by cGMP-dependent protein kinase I (cGKI) (67) . Different studies have demonstrated the implications of the NO-cGMP pathway in the analgesic effect of several drugs that are indicated for the treatment of neuropathic pain, such as tramadol (68), spinal-administered clonidine (69), gabapentin (70, 71) , and also in the antinociceptive effect of anti-inflammatory (72), and in the hyperalgesia evoked by intrathecal high dose morphine (73,74). The NO-cGMP pathway interacts with other signalling pathways (75) such as the cholinergic, adrenergic, purinergic and peptidergic pathways in the peripheral nerve system, and also with endocannabinoids (76) . In pain research, the significance of these interactions of the NO-cGMP pathway with other signalling pathways is only speculative, because they are still poorly understood.
The link between NO and NMDA
The N-methyl-D-aspartate (NMDA) receptor is activated via a voltage-gated ion channel that, once activated, allows Ca 2+ to enter the neuron. It is the increase of intracellular Ca 2+ that triggers the cascade of events that includes activation of a constitutive form of NOS, followed by increased production of NO (77 
NO and peripheral nociception
The role of nitric oxide and cyclic GMP in the periphery has been controversial. Several studies have demonstrated that NO may promote both pro-and antinociceptive effects (80) .
Intracutaneous and paravascular injections of NO in humans can directly evoke pain in a dose-related manner (81, 82). NO-donors led to hypersensitivity in rats (83) and to antinociception in humans (84, 85) . Thus, transdermal NO-donor glyceryl trinitrate was found to act as an antinociceptive when used to treat shoulder pain syndrome due to supraspinatus tendinitis (84) and elbow tendinosis (85) . Topical application of nitric oxide using 13 transdermal glyceryl trinitrate patches can increase blood supply to the region due to local vasodilatation, which in turn increases the clearance of local inflammatory mediators or bioactive proteins such as substance P (85) . It may also stimulate wound fibroblasts and increase fibroblast synthesis, as seen in the healing of tendons (84, 85) . Furthermore, the arginine/NO/cGMP pathway is antinociceptive in subcutaneous tissues, while it is pronociceptive in intradermal tissues (86) . In inflammatory pain, the action of NO depends on the stages of inflammation (80); it is protective during the initial hours after inflammation (80) and cytotoxic later (87) . These studies suggest that NO and cGMP signalling are able to induce pro-or antinociception depending of the different concentrations of NO produced locally (87) , and with a dose-response relationship (88), depending on the location (89) and also on the stage of pathological processes (80) .
Effects of NO in central nervous system
A peripheral nerve lesion gives rise to structural changes in the spinal cord, probably related to the fact that NO acts as a modulator of dorsal horn spinal cord nociceptive pathways (90).
NO is suggested to act as a "retrograde transmitter" because it can easily pass through neuronal membranes. Activation of a receptor results in the production of NO in a postsynaptic neuron from which it rapidly diffuses to enter the presynaptic neuron, where it modulates excitability and enhances synaptic connection (91). Our laboratory is engaged to examine changes in NOS expressions using immunohistochemistry and to relate these changes with morphological alterations in the spinal cord using light microscopy (92). Thus, in our model of chronic neuropathic pain in rats, induced by lesion or ligation of peripheral spinal nerves that induced hyperalgesia behaviour during 4 to 8 weeks after nerve lesion, we reported the role of NO in nociceptive signalling based on the upregulation of neuronal NOS in the superficial dorsal horn and intermediolateral cell column (92). This finding lead to the notion that NO regulates sensory transduction at the spinal cord level. Furthermore, the The brain expresses all three identified nitric oxide synthase isoforms, and NOS activity is higher than in any other tissue (101). In the brain, NO has been proposed to be involved in synaptic plasticity, or to act as a neurotoxin when produced in excess (102).
Cyclo-oxygenase (COX) and NO
Cyclo-oxygenase (COX) converts arachidonic acid into prostaglandins, prostacyclin and thromboxane A 2 . The link between COX and NO pathways was observed in 1993 by Salvemini and co-workers when they demonstrated that the enhanced release of prostaglandines, which follows inflammatory mechanisms, was nearly entirely driven by NO (103). NO is implicated in the regulation of cyclo-oxygenase (104) activity and activates cyclo-oxygenase, followed by an increase in prostaglandin synthesis (105). Nitric oxide 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Potential applications of nitric oxide in pain treatment
Pharmacological modulation of NO levels and NO biosynthesis may be a therapeutic strategy for treating different conditions, including pain (107, 108). 
a. CINODs and the gastrointestinal tract
Gastrointestinal disturbances are a side effect of NSAIDs, and have been attributed to inhibition of gastric COX-1 activity leading to loss of citoprotective prostaglandin (PGI 2 and PGE 2 ) formation. CINODs exploit the functional role of NO in gastric protection, leading to generation of anti-inflammatory drugs that are associated with less gastric toxicity than the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
CINODs. Column 2: interaction between nitric oxide (NO) and COX (cyclo-oxygenase) pathway. NSAID (nonsteroidal anti-inflammatory drugs) inhibit COX1 and COX2 enzymes, followed by prostaglandin (PG) inhibition.
Column 3: NO and NSAID effects. NO-prednisolone has been shown to be more potent than prednisolone alone in a rat model of cholagen induced arthritis (118). COX inhibitors have no effect. In addition, NCX-701 is more potent and, in some circumstances, more effective than its parent compound in different models of inflammatory pain (121). The augmented biological activity of this compound has been assumed to be due to the NO release from nitroparacetamol (122). The NO donating derivate of gabapentin alleviates neuropathic pain-like behaviour after spinal cord and peripheral nerve injury (123).
NO-donating drugs (NODD)
NO
NO-donors (nitroglycerine, isosorbid dinitrate)
These 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 These results are controversial, because the effects of COX-2 inhibitors are not considered efficacious in neuropathic pain. It was previously reported that iNOS and COX-2 pathways interact closely and that iNOS stimulates COX-2 activity (103), and thus it is speculated that this may be why the combination of NOS inhibitors and COX-2 inhibitors was effective in the treatment of neuropathic pain (136). L-NMMA is effective in the treatment of chronic tension-type headache (138, 139) and has also been tested in the treatment of neuropathic pain in humans (140). The mechanism responsible for headache has been studied using the NO-donor (glycerol trinitrate) model for experimental headache in humans (138). The L-NMMA inhibitor of NOS has an analgesic effect in different types of headache such as migraine and cluster-type headache (139).
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Inhibitors of Soluble Guanylyl/Guanylate Cyclase
Methylene blue has direct inhibitory effects on nitric oxide synthases, both constitutive and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In conclusion, we believe that the inhibitors of the NO-cGMP pathway may be a tool for treatment of pain, and we hope that a specific therapeutic strategy will be developed in the near future.
Concluding remarks
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